Consumers Complain To FDA About Albuterol Inhalers, Oxycontin Abuse
Executive Summary
The ombudsman for FDA's Center for Drug Evaluation and Research fielded 660 complaints last year ranging from drug shortage problems to off-label drug promotion and study protocol violations
You may also be interested in...
CDER Ombudsman Referees Increasing Number Of Internal Scientific Disputes
Last year, Virginia Behr, the ombudsman for FDA's Center for Drug Evaluation and Research, dealt with the usual consumer and industry complaints about off-label drug promotion, marketing of unapproved drugs and unethical research conduct. But she also played a greater role mediating scientific disputes between FDA staff
CDER Ombudsman Referees Increasing Number Of Internal Scientific Disputes
Last year, Virginia Behr, the ombudsman for FDA's Center for Drug Evaluation and Research, dealt with the usual consumer and industry complaints about off-label drug promotion, marketing of unapproved drugs and unethical research conduct. But she also played a greater role mediating scientific disputes between FDA staff
Can A REMS Block A Generic? Thalomid Could Be Early Test
Celgene's arguments against generics of Thalomid (thalidomide) offer another example of the potentially vast consequences of FDA's new safety powers: The firm is arguing that the complexity of its risk management plan precludes the approval of alternate versions of the product